Xconomy Profile Reveals More About Prothena, Stock Is Still Too Risky

Last month, Elan(ELN) spun off Prothena(PRTA). As we wrote at the time,  Elan gave Prothena $125 million in cash and a research team with no pipeline. Elan itself now consists mostly of Tysabri, a blockbuster drug on which it is partnered with Biogen Idec(BIIB). We have to admit, we knew very little about Prothena, so we were grateful… Read More »